Michael Horberg to CD4 Lymphocyte Count
This is a "connection" page, showing publications Michael Horberg has written about CD4 Lymphocyte Count.
Connection Strength
2.011
-
Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. J Acquir Immune Defic Syndr. 2016 10 01; 73(2):197-204.
Score: 0.118
-
Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol. 2015 Dec 01; 182(11):952-60.
Score: 0.111
-
The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
Score: 0.111
-
Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care STDS. 2015 Jul; 29(7):370-8.
Score: 0.107
-
Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States. AIDS Patient Care STDS. 2013 Aug; 27(8):442-9.
Score: 0.095
-
Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1630-6.
Score: 0.087
-
Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
Score: 0.074
-
Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):367-73.
Score: 0.072
-
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26.
Score: 0.070
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.068
-
Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
Score: 0.066
-
Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
Score: 0.065
-
Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):531-9.
Score: 0.061
-
New to cohort, not new to care: leveraging historical data in HIV clinical cohorts in the United States. Am J Epidemiol. 2026 08 05; 195(8):2287-2296.
Score: 0.058
-
Prevalence, incidence, and risk factors for dermatologic conditions in people with HIV in the modern antiretroviral era: A cohort study in Washington, DC. J Am Acad Dermatol. 2026 01; 94(1):128-142.
Score: 0.055
-
Evaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation. AIDS Res Ther. 2024 Aug 07; 21(1):52.
Score: 0.051
-
The changing prevalence of anemia and risk factors in people with HIV in North America who have initiated ART, 2007-2017. AIDS. 2023 02 01; 37(2):287-298.
Score: 0.045
-
Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):175-181.
Score: 0.045
-
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. Lancet HIV. 2022 03; 9 Suppl 1:S2.
Score: 0.043
-
Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 06 01; 72(11):1900-1909.
Score: 0.041
-
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
Score: 0.040
-
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 04; 23(4):e25484.
Score: 0.038
-
Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clin Infect Dis. 2020 03 03; 70(6):1176-1185.
Score: 0.037
-
Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. J Acquir Immune Defic Syndr. 2019 09 01; 82(1):71-80.
Score: 0.036
-
A Flow-Based Model of the HIV Care Continuum in the United States. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):548-553.
Score: 0.031
-
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
Score: 0.031
-
Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. AIDS. 2017 04 24; 31(7):989-993.
Score: 0.031
-
Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care STDS. 2017 Mar; 31(3):129-144.
Score: 0.030
-
A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts. J Int AIDS Soc. 2016; 19(1):20707.
Score: 0.029
-
Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016 Jan; 32(1):50-8.
Score: 0.027
-
HIV infection and incidence of ischemic stroke. AIDS. 2014 Aug 24; 28(13):1911-9.
Score: 0.026
-
Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
Score: 0.025
-
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):149-63.
Score: 0.023
-
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
Score: 0.023
-
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med. 2012 Sep 04; 157(5):325-35.
Score: 0.022
-
The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
Score: 0.022
-
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011 Sep 10; 25(14):1771-7.
Score: 0.021
-
Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
Score: 0.019
-
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010 Jun 01; 50(11):1512-20.
Score: 0.019
-
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15; 49(10):1582-90.
Score: 0.018
-
HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13; 23(17):2337-45.
Score: 0.018